Cognition Therapeutics 2025 net loss narrows as expenses fall

Cognition Therapeutics

26/03/2026 11:39

Overview

US biopharmaceutical firm's 2025 net loss narrowed as operating expenses declined

Company ended 2025 with $37 mln in cash, plus $35.7 mln in obligated grant funds

Company expects cash to fund operations through Q2 2027

Outlook

Company expects FDA meeting on DLB psychosis clinical plan by mid-2026

Company estimates cash sufficient to fund operations through Q2 2027

Result Drivers

LOWER R&D SPENDING - Research and development expenses fell due to completion of SHINE and SHIMMER clinical trials and associated professional fees

INCREASED GRANT INCOME - Higher grant income from the National Institute of Aging and related sources helped offset losses

Company press release: ID:nGNXbfdT9q

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$23.49 mln
FY Income From Operations
-$47.80 mln
FY Operating Expenses
$47.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 215.3% above its March 25 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)